The collaboration between the Wellcome Trust Sanger Institute and the Massachusetts General Cancer Center to study the role of genetics in response to cancer treatment is beginning to show results. The study, which began in 2008, released its initial data set, detailing the responses of 350 cancer cell lines to 18 therapeutics. From this, researchers were able to confirm that melanomas with a mutation in the BRAF gene were sensitive to the Astra-Zeneca drug AZ628.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.